Gaudry M, Combadiere C, Marquetty C, Hakim J
INSERM U. 294 and Laboratoire d'Immunologie et d'Hématologie, CHU Xavier Bichat, Université Paris, France.
Immunopharmacology. 1990 Jul-Aug;20(1):45-56. doi: 10.1016/0162-3109(90)90006-z.
Phorbol esters such as phorbol myristate acetate (PMA) and phorbol dibutyrate (PDBU) are generally considered to have similar effects through a similar mechanism, i.e. protein kinase C (PKC) activation. We recently suggested that this was not the case in human neutrophils. To identify further differences between the two phorbol esters, we compared their priming effects on fMet-Leu-Phe-induced superoxide anion (O2-) production, cytosolic PKC activity and binding of fMet-Leu-Phe. Priming could be initiated with a low (0.2 nM) concentration of both PDBU and PMA. Their effects on the pattern of fMet-Leu-Phe-induced superoxide production were similar in both Ca2(+)-containing and Ca2(+)-free medium. PDBU, like PMA, abolished the Ca2+ dependency of fMet-Leu-Phe-induced O2- production in a dose-dependent manner. In cytochalasin B-treated cells and in the presence of Ca2+, priming with PDBU or PMA did not alter the enhancing effect of cytochalasin B on fMet-Leu-Phe-induced O2- production. In Ca2(+)-free medium, priming abolished the Ca2+ dependency of fMet-Leu-Phe stimulation in cytochalasin B-treated cells. Cytochalasin B, however, enhanced the effect of PMA but not that of PDBU. Priming with PDBU was not associated under any experimental conditions with a decrease in cytosolic PKC activity, or an increase in PKM activity before or after fMet-Leu-Phe stimulation. Furthermore, priming effects were abolished by cell washing but not by H-7 or staurosporine, which are potent PKC inhibitors. PDBU, in contrast to PMA, increased fMet-Leu-Phe binding to PMNs through a decrease in the dissociation constant and induced degranulation of specific granules as measured by the release of vitamin B12 binding protein. These findings show that the priming effects of PDBU differ in certain respects from those of PMA, namely with regard to its synergism with cytochalasin B and the expression of fMet-Leu-Phe receptors. In addition, priming concentrations of PDBU, like PMA, did not alter cytosolic PKC activity in fMet-Leu-Phe-stimulated neutrophils.
佛波酯,如佛波醇十四酸酯乙酸盐(PMA)和佛波醇二丁酸酯(PDBU),通常被认为通过类似的机制产生类似的效应,即蛋白激酶C(PKC)激活。我们最近提出在人类中性粒细胞中情况并非如此。为了进一步确定这两种佛波酯之间的差异,我们比较了它们对fMet-Leu-Phe诱导的超氧阴离子(O2-)产生、胞质PKC活性以及fMet-Leu-Phe结合的启动作用。低浓度(0.2 nM)的PDBU和PMA均可启动该作用。在含Ca2+和无Ca2+的培养基中,它们对fMet-Leu-Phe诱导的超氧产生模式的影响相似。与PMA一样,PDBU以剂量依赖的方式消除了fMet-Leu-Phe诱导的O2-产生对Ca2+的依赖性。在用细胞松弛素B处理的细胞中且存在Ca2+的情况下,用PDBU或PMA启动不会改变细胞松弛素B对fMet-Leu-Phe诱导的O2-产生的增强作用。在无Ca2+培养基中,启动消除了细胞松弛素B处理的细胞中fMet-Leu-Phe刺激对Ca2+的依赖性。然而,细胞松弛素B增强了PMA的作用,但未增强PDBU的作用。在任何实验条件下,用PDBU启动均与fMet-Leu-Phe刺激前后胞质PKC活性的降低或PKM活性的增加无关。此外,通过细胞洗涤可消除启动作用,但强效PKC抑制剂H-7或星形孢菌素不能消除该作用。与PMA相反,PDBU通过降低解离常数增加了fMet-Leu-Phe与中性粒细胞的结合,并通过维生素B12结合蛋白的释放来衡量诱导了特异性颗粒的脱颗粒。这些发现表明,PDBU的启动作用在某些方面与PMA不同,即在与细胞松弛素B的协同作用以及fMet-Leu-Phe受体的表达方面。此外,与PMA一样,PDBU的启动浓度不会改变fMet-Leu-Phe刺激的中性粒细胞中的胞质PKC活性。